Clinical Trial

Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective is to investigate if abrupt withdrawal versus gradual withdrawal of pharmacotherapy (solifenacin and/or mirabegron) influences the risk of recurrence of incontinence. Children aged 5-14 years diagnosed with urinary incontinence, treated with pharmacotherapy of solifenacin and/or mirabegron and ready for withdrawal will be randomized 1:1 to either abrupt or gradual withdrawal, according to the medical treatment that the child is receiving.
Trial Details
NCT Number NCT06465576
Lead Sponsor University of Aarhus
Conditions Urinary Incontinence in Children
Enrollment 216 participants
Start Date 2024-05-27
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-08